Influence of genetic polymorphisms in p2y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

HIGHLIGHTS

• who: Yan-Jiao Zhang from the A total of , consecutive CHD patients treated with clopidogrel from Xiangya Hospital, Central South University from September , to November , in this prospective clinical studyThe age of the patients ranged from , to , years. These samples were divided into discovery (n=239) and validation (n=300) sets. All patients received dual antiplatelet therapy (DAPT) with aspirin and oral administration of , mg loading dose (LD) clopidogrel, or , mg daily maintaining dose (MD) of clopidogrel for at least , days. Venous blood samples were drawn in, :00-7:, Am, h after LD of clopidogrel or on . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.